openPR Logo
Press release

Biopharma PEG Expands Multi-Arm PEG Product Line

08-28-2024 08:39 AM CET | Chemicals & Materials

Press release from: Biopharma PEG Scientific Inc

Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm PEG linkers with diverse functional groups and molecular weights from 1k to 40k," said Sonia Lee, Biopharma PEG. "Our multi-arm PEG derivatives are widely recognized as smart cross-linkers, and they have been extensively studied for their ability to form hydrogels. These hydrogels are pivotal in medical devices, regenerative medicine, drug delivery systems, 3D cell culture, and wound healing."
Diverse Product Offering: Biopharma PEG's multi-arm PEG products are available with various branching structures and functional groups to meet the specific needs of researchers and developers in the medical and bioorganic fields. Key product categories include:
 2-Arm PEG (Y-shape PEG, branched PEG): Ideal for applications requiring a branched structure, such as Y-shape-PEG-NHS.
 4-Arm PEG: Available in options like 4-ArmPEG-SG, 4-ArmPEG-SS, and 4-ArmPEG-NH2, these linkers provide enhanced cross-linking capabilities.
 8-Arm PEG: Examples include 8-ArmPEG-SG, 8-ArmPEG-SS, and 8-ArmPEG-Mal, offering maximum branching for complex hydrogel formation.
These products are offered in molecular weights of MW 2k, MW 5k, MW 10k, MW 20k, and MW 40k, allowing for precise control over the physical and chemical properties of the final hydrogel structures. The total molecular weight of each multi-arm PEG product is calculated as the sum of the molecular weights of the PEG chains on each arm.
Key Applications in Medicine: Multi-arm PEG linkers from Biopharma PEG are vital in several advanced medical applications:
 Controlled Drug Release: The cross-linked hydrogels formed by multi-arm PEGs provide a stable matrix for the sustained and controlled release of drugs, ensuring targeted delivery and enhanced therapeutic efficacy.
 3D Cell Culture: Multi-arm PEG hydrogels create a supportive, biocompatible environment that mimics natural tissue, making them ideal for 3D cell culture and tissue engineering.
 Wound Sealing and Healing: Multi-arm PEG hydrogels are increasingly used in wound care, offering effective sealing properties that promote faster healing and reduce the risk of infection.
Custom Solutions for Specialized Needs: In addition to the standard product offerings, Biopharma PEG provides custom synthesis of multi-arm PEGs with specific molecular weights and functional groups not listed in the online catalog. This allows researchers and developers to tailor PEG linkers to their unique project requirements. Inquiries for custom synthesis can be directed to sales@biochempeg.com, where our team is ready to assist with pricing and availability.
Contact Information: For more details on Biopharma PEG's high-purity multi-arm PEG linkers or to explore custom synthesis options, please visit www.biochempeg.com or reach out to our team at sales@biochempeg.com.

Biopharma PEG Scientific Inc.
108 Water Street, Suite 4D, Watertown, MA 02472, USA
TEL: 1-857-928-2050 / 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com

Biopharma PEG is a premier supplier of PEG derivatives, committed to advancing the pharmaceutical, biotechnology, and medical device industries with innovative products that enhance the performance of therapeutic agents. Discover more at www.biochempeg.com.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biopharma PEG Expands Multi-Arm PEG Product Line here

News-ID: 3636890 • Views:

More Releases from Biopharma PEG Scientific Inc

BIOPHARMA PEG Receives FDA DMF Listings for Two Key PEG Derivatives
BIOPHARMA PEG, a leading developer and supplier of high-purity polyethylene glycol (PEG) derivatives, today announced that two of its proprietary products-mPEG-pALD 20K and HZ-PEG-HZ (1K)-have successfully passed FDA review and are now listed in the U.S. Drug Master File (DMF) database. mPEG-pALD (20K) - DMF No. 040600 HZ-PEG-HZ (1K) - DMF No. 041864 These new listings mark a significant step in BIOPHARMA PEG's ongoing efforts to provide regulatory-ready, high-quality PEG solutions to the
Monodispersed PEG Linkers Enhance Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) linkers between the antibody and drug payload can address this. PEG is hydrophilic, biologically inert, and FDA‐recognized as safe. As a flexible spacer, PEG "shields" the hydrophobic drug, greatly improving ADC solubility and stability. In fact,
Biopharma PEG Scientific Inc. to Showcase Comprehensive PEG Derivative Portfolio at TIDES USA 2025
Biopharma PEG Scientific Inc. to Showcase Comprehensive PEG Derivative Portfolio …
Biopharma PEG Scientific Inc., a leading provider of high-quality polyethylene glycol (PEG) derivatives, today announced its participation in TIDES USA 2025, taking place from May 19 - 22, 2025, at the Manchester Grand Hyatt San Diego. Attendees are invited to visit Biopharma PEG at Booth #913 to explore their extensive range of GMP-grade PEG products and discuss how these solutions can advance their research and development efforts. Biopharma PEG offers a
BIOPHARMA PEG Showcases DSPE-PEG-Mannose: A Cutting-Edge Polymer for Drug Delive …
Watertown, MA - March 24, 2025 - Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion. Structural Advantages of DSPE-PEG-Mannose DSPE-PEG-Mannose is composed of three key components that enable its diverse applications: DSPE (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine): A phospholipid with amphiphilic properties, forming stable micelles in aqueous solutions. PEG (Polyethylene Glycol): A biocompatible polymer

All 5 Releases


More Releases for Key

Caprylyl Glycine Market Size, Share and Forecast By Key Players-Key Player I, Ke …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Caprylyl Glycine market is anticipated to grow at a compound annual growth rate (CAGR) of 16.41% between 2024 and 2031. The market is expected to grow to USD 11.09 Billion by 2024. The valuation is expected to reach USD 32.12 Billion by 2031. The Caprylyl Glycine market is experiencing significant growth, driven by its increasing demand in the
Polyurethane Prepolymer (PPU) Market Size, Share and Forecast By Key Players-Key …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Polyurethane Prepolymer (PPU) market is anticipated to grow at a compound annual growth rate (CAGR) of 11.68% between 2024 and 2031. The market is expected to grow to USD 8.1 Billion by 2024. The valuation is expected to reach USD 17.54 Billion by 2031. The Polyurethane Prepolymer (PPU) Market is set for significant growth, driven by increasing demand
Olivine Sand Market Size, Share and Forecast By Key Players-Key Player I, Key Pl …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Olivine Sand market is anticipated to grow at a compound annual growth rate (CAGR) of 16.07% between 2024 and 2031. The market is expected to grow to USD 39 Billion by 2024. The valuation is expected to reach USD 110.69 Billion by 2031. The olivine sand market is poised for significant growth due to its increasing use in
Phlorotannins Market Analysis By Top Keyplayers - Key Player I, Key Player II, K …
The "Phlorotannins Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031.  The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Phlorotannins Market, 2024-2031 Verified Market Research's most recent report, "Phlorotannins Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the industry
Direct Drive Frameless Motor Market Size, Insights 2031 by Key Vendors- Key Play …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Direct Drive Frameless Motor Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a 𝐂𝐀𝐆𝐑 𝐗𝐗.𝐗% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟏. The Direct Drive Frameless Motor Market presents significant opportunities for growth driven by advancements in technology and the increasing demand for high-performance, precision-driven applications across various industries.
Hydroxylamine Hcl Market Size, Share Projections 2031 by Key Manufacturer- Key P …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Hydroxylamine Hcl Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a 𝐂𝐀𝐆𝐑 𝐗𝐗.𝐗% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟏. The Hydroxylamine HCl Market offers substantial opportunities for growth driven by its diverse applications across various industries. Hydroxylamine hydrochloride is widely used as a reducing agent in chemical synthesis,